Treatment of patients with chronic bacterial prostatitis

Krupin, Valentin N.; Белова, А. Н.; Krupin, Alexey V.

doi:10.21886/2308-6424-2019-7-1-26-37

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…chronic bacterial prostatitis, Adenoprosin ® , inflammation, culture and microscopy of prostatic fluid. Cite this article as: [6][7][8][9]. Стандартная антибактериальная терапия в большинстве случаев не приводит к уменьшению количества рецидивов заболевания, в связи с чем часто применяют комплексный подход и также назначают биостимуляторы, экстракты различных растений и насекомых и их биологических компонентов [10].…”

Section: Introductionunclassified

The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis

Медведев¹,

Yefremov²

2020

Innovacionnaâ medicina Kubani

View full text Add to dashboard Cite

Background. Chronic bacterial prostatitis is a common disease clinically diagnosed based on signs of inflammation and the presence of infection in the prostatic fluid. Standard antibiotic therapy in most cases does not lead to a decrease in the number of recurrences. In this connection, an integrated approach is often used in therapy, and in addition to antibacterial therapy, biostimulators, extracts of various plants and animals are prescribed. One of the main advantages of these prescriptions is that the drugs have minimal side effects.Objective. To assess the effectiveness of the use of Adenoprosin® in the combined treatment of patients with chronic bacterial prostatitis.Material and methods. 60 patients aged from 24 to 50 years old (average age is 31.3 ± 2.8 years) with a diagnosis of chronic bacterial prostatitis were examined and treated, the duration of the disease ranged from 6 months to 15 years (average duration of the disease is 1.5 ± 0.3 years). The patients were divided into two groups: group I included 30 patients who were treated with antibacterial drugs and Adenoprosin®, group II included 30 patients who were treated with antibacterial drugs only. The course of treatment lasted 30 days, the total time of observation of the patients was 3 months. Clinical control was carried out at the first visit to the urologist, on the 14th, 28th, 45th and 90th days from the start of therapy and included filling out the following: The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), The International Prostate Symptom Score (IPSS) and Quality of Life (QoL), as well as the International Index of Erectile Function (IIEF-5) questionnaire in order to identify the possible effect of therapy on sexual function.Results. The analysis revealed that the use of the Adenoprosin® in complex therapy in patients with chronic bacterial prostatitis reduces the overall score of the NIH-CPSI questionnaire by an average of 4 points. When conducting a questionnaire at the end of treatment, 2 (6.6%) patients in the group II noted dissatisfaction with the therapy, on the 90th day of observation, complaints of dissatisfaction with the treatment remained in 1 (3.3%) patient. In 5 (16.6%) patients of the group II, against the background of the therapy, there was no subjective improvement in the treatment; on the 90th day of observation, the number of unsatisfied patients remained the same. Analysis of the results of microscopy of the prostatic fluid and microflora after treatment on day 28 showed the decrease in the content of leukocytes in the group I patients – less than 10 leukocytes in the field of vision in 25 (80%) patients, which was higher in comparison with patients of the group II – 21 (70%). In 5 (16.6%) patients of the group I, the number of leukocytes in the prostatic fluid was in the range of 10–20 in the field of view, all patients had previously had recurrent forms of the disease. The number of leukocytes more than 10, after antibacterial therapy in the group II, was in 7 (23.3%) patients, of them 5 (16.6%) patients had recurrent forms of the disease, and 2 (6.6%) patients were diagnosed with prostatitis for the first time. Thus, the use of combination therapy in the group I, to a greater extent, reduced the inflammatory markers of the disease.Conclusion. The Adenoprosin® in complex therapy has a proven anti-inflammatory effect on the prostate gland, reduces the pain rapidly, decreases the total score of prostatic symptoms when analyzing the NIH-CPSI questionnaires, improves erectile function, reduces markers of inflammation in the pre-fetal gland and can be recommended for patients with chronic bacterial inflammation in the prostate gland.

show abstract

Section: Introductionunclassified

The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis

Медведев¹,

Yefremov²

2020

Innovacionnaâ medicina Kubani

View full text Add to dashboard Cite

show abstract

Complex conservative therapy of chronic abacterial prostatitis

Neymark

Борисенко

et al. 2021

Urology reports (St. - Petersburg)

View full text Add to dashboard Cite

BACKGROUND: Improving the results of treatment of patients with chronic prostatitis is one of the important problems of modern urology. AIM: To compare the effect of ozone therapy and hypercapnic therapy on the hemodynamics of the prostate and immune status in patients with chronic abacterial prostatitis. MATERIALS AND METHODS: The study included 58 patients with chronic abacterial prostatitis, who were divided into three groups. Patients of the 1st group (n = 18) received standard therapy. Patients of the 2nd group additionally underwent a course of transrectal ozone therapy for 10 days. Patients of the 3rd group, in addition to the basic therapy, performed training on a breathing simulator to obtain the effect of hypercapnic hypoxia; the course of treatment consisted of 10 daily trainings. The effectiveness of therapy was assessed using the NIH-CPSI questionnaire. To assess the immune status of patients, we studied the content of IgA, IgG and IgM in the blood, the activity of the pro-inflammatory cytokines IL-1, TNF-, IL-6 in the blood serum and IL-8 in the urine. The state of blood flow in the prostate gland was assessed using laser Doppler flowmetry, as well as TRUS performed in the color Doppler imaging mode. The control group included 22 healthy men. RESULTS: In patients with chronic abacterial prostatitis hemodynamic and microcirculatory changes in the prostate gland were revealed, which were accompanied by characteristic clinical manifestations, urinary disorders, as well as impaired immune status in the form of an increase in the content of interleukins and tumor necrosis factor. The use of basic therapy (1st group) helps to reduce the clinical manifestations of chronic abacterial prostatitis, but its effect on the immune status, hemodynamics and microcirculation of the prostate gland is insufficiently expressed. Complex therapy, supplemented by training on a breathing simulator using the effect of hypercapnic hypoxia, has a positive effect on the course of the disease (3rd group). This type of therapy is able to improve the microcirculation of the prostate gland, increasing the index of microcirculation efficiency and average blood flow, reducing the shunting rates, but its effect on immunity is lower than in patients whose treatment included transrectal ozone therapy (2nd group). This type of treatment leads to a decrease in the activity of the pro-inflammatory cytokines IL-1, TNF-, IL-6 in the blood serum, and IL-8 in the urine, but at the same time does not have a sufficient effect on prostate hemodynamics and microcirculation. CONCLUSIONS: In patients with CAP with pronounced disorders of the immune status, complex treatment is indicated, supplemented by transrectal ozone therapy, and in the presence of pronounced hemodynamic disorders of the prostate gland, complex therapy is indicated, supplemented by the use of the effect of hypercapnic hypoxia.

show abstract

Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Ибишев

Naboka

Krainiy³

et al. 2022

Vestn. Urol.

View full text Add to dashboard Cite

Introduction. The tactics of managing and treating patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult-to-treat condition for a practicing urologist. This circumstance occurs because the disease has several predisposing factors, a complex and multifaceted pathogenesis, and certain difficulties in diagnosis and treatment.Objective. To study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in prostate secretion.Materials and methods. The treatment of 52 post-COVID-19 patients with CRBP was analyzed, divided into three therapy-dependent groups. Group 1 patients (n = 18) received antibiotic therapy (ABT): Levofloxacin 500 mg q.d. PO for 28 days. Group 2 patients (n = 18) underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®” rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (“Viferon®”rectal suppositories) 3.000.000 IU b.i.d. PR q12h for 28 days. The follow-up period was 6 months with monitoring of clinical and laboratory parameters assessed before treatment, after 1, 3 and 6 months from the start of therapy.Results. Based on the monitoring of the clinical picture and laboratory parameters, after 1 follow-up month, there was a significant decrease in the symptoms of the disease in all study groups. However, after 3 and 6 follow-up months, this trend was observed only in patients of groups 2 and 3 receiving recombinant interferon alfa-2b with an antioxidant complex (vitamins E and C).Conclusions. Strengthening the standard CRBP-therapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C makes it possible to normalize both clinical and laboratory parameters in most patients.

show abstract

Treatment of patients with chronic bacterial prostatitis

Cited by 4 publications

References 8 publications

The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis

The efficacy of Adenoprosin® in combined treatment of patients with chronic bacterial prostatitis

Complex conservative therapy of chronic abacterial prostatitis

Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Contact Info

Product

Resources

About